Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis Pharmaceuticals's other current liabilities for the quarter that ended in Jun. 2026 was MXN1,320 Mil.
Ionis Pharmaceuticals's quarterly other current liabilities
declined
from Dec. 2025 (MXN2,093 Mil) to Mar. 2026 (MXN1,074 Mil) but then
increased
from Mar. 2026 (MXN1,074 Mil) to Jun. 2026 (MXN1,320 Mil).
Ionis Pharmaceuticals's annual other current liabilities
increased
from Dec. 2023 (MXN1,150 Mil) to Dec. 2024 (MXN1,452 Mil) and
increased
from Dec. 2024 (MXN1,452 Mil) to Dec. 2025 (MXN2,093 Mil).
Ionis Pharmaceuticals Other Current Liabilities Related Terms
Ionis Pharmaceuticals Other Current Liabilities Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Other Current Liabilities Chart
Ionis Pharmaceuticals Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of MXN1,320 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Other Current Liabilities of MXN1,320 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ionis Pharmaceuticals.
Is Ionis Pharmaceuticals' Other Current Liabilities too high?
Ionis Pharmaceuticals' current Other Current Liabilities is MXN1,320 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Other Current Liabilities compare to KYMR and PRAX?
Ionis Pharmaceuticals' Other Current Liabilities of MXN1,320 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ionis Pharmaceuticals. Ionis Pharmaceuticals's current Other Current Liabilities is MXN1,320 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Other Current Liabilities of MXN1,320 Mil. The stock's GF Value™ is MXN909.60, compared to a current price of MXN1,010.00 — trading 11% above its estimated fair value. The current Other Current Liabilities is MXN1,320 Mil. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Other Current Liabilities is MXN1,320 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,010.00 is trading 11% above its estimated GF Value™ of MXN909.60.
Key valuation signals for MEX:IONS:
Other Current Liabilities: MXN1,320 Mil
GF Value™: MXN909.60 vs. price of MXN1,010.00 (11% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score
Get the complete analysis for MEX:IONS
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
